eligibility_summary
Adults ≥18 with advanced/metastatic esophageal, gastric, or GEJ adenocarcinoma, progression after 1 prior metastatic line or during/≤6 mo after (neo)adjuvant, RECIST measurable/evaluable disease, ECOG 0–1, adequate marrow/renal/hepatic function. Exclude prior ramucirumab, taxane ≤6 mo, severe prior ICI irAE, immunodeficiency/recent immunosuppression, GI perforation/fistula, active TB/CNS mets/meningitis/pneumonitis, ADL-limiting neuropathy, HIV, active HBV/HCV, live vaccine ≤30 d, noncompliance, pregnancy/breastfeeding, or no consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in previously treated advanced esophageal/gastric/GEJ adenocarcinoma testing a 5-drug combo: 1) agenT-797: allogeneic unmodified invariant natural killer T (iNKT) cell therapy, iNKT cells recognize glycolipid antigens via CD1d, secrete Th1 cytokines, and activate NK, CD8 T cells, and macrophages to kill tumor and remodel the TME. 2) Botensilimab: Fc-engineered IgG1 anti-CTLA-4 antibody, blocks CTLA-4 to enhance T-cell priming and depletes intratumoral Tregs via Fc effector function. 3) Balstilimab: anti-PD-1 antibody, reverses T-cell exhaustion. 4) Ramucirumab: anti-VEGFR2 antibody, inhibits VEGF-driven angiogenesis. 5) Paclitaxel: taxane cytotoxic, stabilizes microtubules causing mitotic arrest and may increase tumor antigen release. Targets: iNKT/CD1d axis, CTLA-4 and PD-1 on T cells/Tregs, VEGFR2-VEGF angiogenesis, tumor cell microtubules.